|
Jun 17
|
Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy
|
|
Jun 17
|
Generic Drugmakers Resist Trump’s Calls for More U.S. Manufacturing
|
|
Jun 17
|
Teva, Fosun Pharma partner to develop TEV-56278
|
|
Jun 17
|
Teva to collaborate with Fosun Pharma for TEV-56278
|
|
Jun 16
|
Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology
|
|
Jun 16
|
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
|
|
May 29
|
Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day
|
|
May 28
|
TEVA Begins IND-Enabling Studies on Inflammatory Disease Candidate
|
|
May 28
|
Billionaire Stanley Druckenmiller Just Sold One of Wall Street's Hottest Stock-Split Stocks and Is Piling Into a Promising Drugmaker Instead
|
|
May 28
|
Teva Pharmaceutical Industries Limited (TEVA) Wins FDA Fast Track for Celiac Disease Drug TEV-53408
|
|
May 27
|
Teva Celiac Disease Candidate Granted Fast Track Designation by US FDA
|
|
May 27
|
Teva to Present at Jefferies Global Healthcare Conference and Goldman Sachs Global Healthcare Conference in June
|
|
May 27
|
Why Is Teva Stock Trading Higher On Tuesday?
|
|
May 27
|
TEVA Stock Up Around 13% in a Month: Buy, Sell or Hold the Stock?
|
|
May 27
|
Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma
|
|
May 26
|
Regulatory Shake-Up Led to the Sell Off in Teva Pharmaceutical Industries Limited (TEVA)
|
|
May 22
|
Teva Announces Increase of the Maximum Tender Amount of its Debt Tender Offer and Increases to Pool Tender Caps for Pool 2 Notes and Pool 3 Notes
|
|
May 19
|
Teva Announces $2,000,000,000 (Equivalent) Debt Tender Offers For Notes Due 2026-2031
|
|
May 19
|
Teva Announces Launch of $2,000,000,000 (Equivalent) Offering of Senior Notes
|
|
May 15
|
Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
|